Weston Daniel: A Powerful Reminder That Behind Every Cell Culture Assay are Real People
Weston Daniel, Chief Development Officer (CDO) at EVOQ Therapeutics, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Results from a Phase 1b/2 clinical study—part of a program I had the privilege to lead over many years—have just been published.
This multi-year journey brought together a remarkable team of scientists, oncologists, CRO partners, and expert consultants. I’m deeply grateful for the collaboration and commitment that made this work possible.
Most importantly, the study delivered meaningful clinical responses in a subset of patients with advanced cancer that had progressed on state of the art immunotherapy.
It’s a powerful reminder to me that behind every cell culture assay, every regulatory document, and every conference call, there are real people waiting for better options.”
Title: Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
Authors: Mohammed Milhem, Trisha Wise-Draper, Sunandana Chandra, Glenn Hanna, Douglas Laux, Theresa Medina, George Ansstas, Adil Daud, Ciara Kelly, Steven O’Day, Cesar Perez, Michael Wong, Philip Friedlander, Timothy Kristedja, Melissa Burgess, Lance Cowey, Brent Hanks, Ryan Weight, Weston Daniel, Douglas Feltner, Scott Mix, Laurel Sindelar, Alice Bexon, Martin Bexon, Robert Michel, Shailender Bhatia
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Advanced Solid Tumors.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023